

---

## Global Sepsis Innovations Platform (GSIP)

---

The **Global Sepsis Innovations Platform (GSIP)** is a new global public-private partnership platform that set to launch on January 30, 2025 by the [Global Sepsis Alliance](#) (GSA) in collaboration with the [Sepsis Stiftung](#) (Germany). [Sepsis Alliance](#) (US) which has initiated and led the Sepsis Innovation Collaborative, will join the GSIP as a Member.

Aligned with the [2030 Global Agenda for Sepsis](#) - the first multi-year global strategy for Sepsis, which was launched at the German Parliament in September 2024 - GSIP aims to foster coordinated ongoing discussions and advocacy to address unmet needs in Sepsis innovations. This includes research & development (R&D) for novel vaccines and other prevention interventions, diagnostics, antimicrobial and immunomodulatory therapies, precision medicine, care and rehabilitation commodities, and AI-enabled technologies.

The GSIP will serve as a collaborative platform for:

1. **Knowledge Exchange.** Facilitating collaboration among innovators, researchers, healthcare professionals, Sepsis survivors, and patients' families. Engaging Sepsis survivors ensures that the platform remains focused on addressing unmet needs in prevention, diagnostics, and therapeutics, as well as innovations for post-Sepsis care and rehabilitation. The platform will also prioritize discussions on Sepsis response during emergency situations and humanitarian crises for both civilians and military personnel.
2. **Regulatory Collaboration.** Promoting multilateral discussions, consensus-building, and recommendations regarding regulations related to R&D, authorization, and licensing of Sepsis innovations. Where appropriate, GSIP will submit recommendations and position statements to national and regional regulatory authorities, including the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the African Medicines Agency (AMA).
3. **Advocacy Coordination.** Coordinating efforts with national governments, philanthropic foundations, the private sector, the manufacturing industry, public-private partnerships, and research institutions, with active engagement of Sepsis

survivors and families with lived experiences. The aim of coherent advocacy is to increase investment in Sepsis research and innovations and to prioritize Sepsis as a leading cause of death for children, women, and men worldwide.

4. **Operational Research Coordination.** Supporting discussions, planning, and implementation of operational research to define the accessibility and affordability of basic Sepsis-related equipment and supplies, with particular attention to low- and middle-income countries (LMICs), which bear the highest burden of sepsis. As an example, the effort will be built upon pioneering research work by Scheer et al “Sepsis Care, Diagnostics and Quality Management: A Multidisciplinary Cross-Sectional Survey in 73 Countries”, documenting that even in the EU region and countries, only 10% of hospitals had 24/7 access to culture incubations, and early recognition measures for Sepsis were available in 47% of emergency medical services (EMS) and 61% of intensive care units (ICUs).
5. **Defining the Sepsis R&D Agenda.** Facilitating discussions to identify the Sepsis R&D priorities, especially for LMICs, including unmet needs in Sepsis data (both quantitative and qualitative), traditional and novel vaccines, early detection and treatment strategies, and AI solutions for Sepsis diagnostics and management. The work will also build upon the Sepsis Science Info Centre, led by the Sepsis Stiftung, which curates the latest global publications and research findings on sepsis

---

## Launch and Operationalization

---

- The Global Sepsis Innovations Platform (GSIP) will be launched on January 30, 2025, in Berlin through a hybrid meeting that will bring together members and partners of the platform. The event will engage representatives from the Global Sepsis Alliance (GSA), Sepsis Stiftung, Sepsis Alliance, Regional Sepsis Alliances for Africa, Asia-Pacific, the Eastern Mediterranean, Europe, and the Caribbean, the Latin American Sepsis Institute, GSA members and partners from North America, members of the European Sepsis Alliance Patient and Family Support Working Group, sepsis survivors, patient families from various regions, and stakeholders from the public, private, academic, and civil society sectors interested in joining GSIPGSIP
- The GSIP Secretariat will be co-hosted by the Global Sepsis Alliance, the largest professional network of Sepsis experts and advocates, which champions the 2030

Global Agenda for Sepsis, and the German Sepsis Foundation (Sepsis Stiftung), known for its work on the Sepsis Science Info Centre, Sepsis checklists, and other innovative initiatives.

- **Bi-monthly and ad hoc GSIP meetings** will be held in a hybrid format to engage GSIP members and partners globally, with the chairmanship rotating between the Global Sepsis Alliance (GSA) and Sepsis Stiftung.
- In collaboration with GSIP member and partner organizations, **working groups** will be established to facilitate focused discussions on innovations in prevention, diagnosis, treatment, and post-sepsis rehabilitation, as well as to set priorities for evidence generation. Given the high disease burden in children, a **special working group** for Pediatric Sepsis Innovations is also recommended.
- Below is the proposed list of **GSIP Working Groups**, subject to further discussion and agreement by GSIP members:
  - a. **Sepsis Prevention Working Group.** This group will focus on discussions and recommendations regarding vaccines, water, sanitation, and hygiene (WASH), antimicrobial resistance (AMR) stewardship, and other infection prevention and control measures in both healthcare and community settings.
  - b. **Sepsis Diagnostics Working Group.** This group will address unmet needs in the early detection of Sepsis, including advancements in microbiology labs, point-of-care diagnostics, and AI-driven solutions.
  - c. **Sepsis Treatment and Care Working Group.** The group will cover discussions and recommendations on antimicrobial therapies (including antibiotics, antivirals, antifungals, and antimalarials), immunomodulatory therapies, precision medicine, theragnostic solutions and innovations in post-Sepsis care and rehabilitation.
  - d. **Sepsis Data and Evidence Working Group.** This group will explore novel approaches to Sepsis data generation, modeling, and analysis, as well as operational research aimed at addressing data gaps, particularly in low- and middle-income countries (LMICs).
  - e. **Paediatric Sepsis Innovations Working Group.** Finally, this group will ensure focused discussions on Sepsis prevention, diagnostics, and treatment for children, with a special emphasis on the regions most affected by sepsis, particularly Sub-Saharan Africa and South Asia.
- The **Working Groups** will be established and led by stakeholders from diverse geographic regions within GSIP, following transparent discussions, nominations,

and an election process. These groups will meet monthly or bi-monthly and will submit relevant recommendations to the GSIP bi-monthly meetings for further discussion and decision-making.

- The work of the GSIP platform and the **Working Groups** will be promoted through the websites and social media channels of the Global Sepsis Alliance (GSA), Sepsis Stiftung, and the Regional Sepsis Alliances for Africa, Asia-Pacific, the Eastern Mediterranean, Europe, and the Caribbean.

---

### Proposed In-kind and Financial Contributions

---

The Global Sepsis Alliance and the Sepsis Stiftung are proposing the following membership, sponsorship and partnership packages for the Global Sepsis Innovations Platform (GSIP) for the 2025 fiscal year.

- **GSIP Membership for non-profit sector.** Representatives of the Regional Sepsis Alliances (2 representatives per Alliance from organizations in good standing), Patient and Family Support Working Group of the European Sepsis Alliance and the Global Patient Group for Sepsis will be eligible for the GSIP membership at no financial cost. Members of the GSA in good standing, can also participate in the GSIP work at no additional financial cost.
- **Membership and Partnership fees for private sector.** Representatives of the private sector can join the platform as **GSIP Members** (€ 5,000 annual fee), **GSIP Partners** (€ 10,000 annual contribution), **GSIP Visionary Partners** (€ 25,000 annual contribution) or **GSIP Strategic Partners** (€ 50,000 annual contribution).
- For further information, please contact the Berlin head office of the Global Sepsis Alliance at [Simone.Mancini@global-sepsis-alliance.org](mailto:Simone.Mancini@global-sepsis-alliance.org)